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Abstract
Endothelial progenitor cells (EPCs) are a group of rare cells that play an important role in the
repair of injured vascular endothelial cells and assist in reperfusion of ischemic tissue.
Decreased production and/or loss of function of EPCs are associated with diabetic vasculo-
pathy. The molecular mechanisms by which diabetes impairs EPCs remain unclear. We
conducted microarray experiments followed by integrative regulatory analysis on cells iso-
lated from Akita diabetic mice (18-weeks after onset of diabetes) and age-matched non-dia-
betic controls. Two types of cells were isolated frommice bone marrow; Lin+ cells and Lin-/
VEGF-R2+ EPCs. RNA was hybridized tomouseWG-6 V2 beadchips followed by compre-
hensive gene network analysis and computational validation of the obtained results. In total,
80 genes were exclusively DE between non-diabetic Lin-/VEGF-R2+ EPCs and diabetic
Lin-/VEGF-R2+ EPCs, of which the 3 genes Clcnka, Pik3c2a, and Ptf1a are known to be
associated with diabetic complications. Further analysis led to the establishment of a TF-
miRNA mediated regulatory network specific to diabetic Lin-/VEGF-R2+ EPCs and to iden-
tify 11 central-hub TFs (Tbp, Ahr, Trp53,Gata1, Foxo1, Foxo4, Yy1,Max, Pparg,Myc,
Cebpa), and 2 miRNAs (mir-139-5p,mir-709) that might act as putative genomic drivers of
diabetic pathogenesis in Lin-/VEGF-R2+ EPCs. Moreover, we identified multiple TF-miRNA
co-regulatory network motifs for which we validated their contribution to diabetic Lin-/VEGF-
R2+ EPCs in terms of statistical significance and relevance to biological evidence. Our find-
ings suggest that diabetic Lin-/VEGF-R2+ EPCs have specifically altered signature genes
and miRNAs that render their capacity to proliferate and differentiate.
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Introduction
Chronic diabetes is associated with injury of vascular endothelial cells (ECs) [1] that is believed
to be repaired by neighboring resident endothelial cells, resident endothelial progenitor cells
(EPCs), and bone marrow (BM) derived EPCs [2]. It has been reported that diabetes is associ-
ated with impairment of EPC function [3]. Diabetic patients were shown to have reduced EPC
numbers in the peripheral blood (PB) [4] and the isolated PB EPCs showed impaired prolifer-
ate, tubes formation, adhesion and were less effective in repairing vascular injuries [5]. Several
studies suggest that reduced number and/or dysfunction of EPCs in cell mobilization, prolifer-
ation, adhesion, and incorporation into the vasculature may contribute to diabetic vascular
complications [6].
Recently, we reported an impaired mobilization capacity of BM Lin-/VEGF-R2+ EPCs in
diabetic mice [7]. EPCs are usually defined based on their surface markers and proliferative
and clonogenic potential and they are believed to be lineage and functionally heterogeneous
[2]. It has been suggested that an insult to the stem cell niche might contribute to reduction in
the numbers and impairment of EPC function [8]. These Lin-/VEGF-R2+ EPCs play an impor-
tant role in regenerating the endothelium through migration, proliferation, differentiation and
by secreting pro-angiogenic cytokines [9].
The majority of molecular studies on the impairment of diabetic EPCs (D-EPCs) function
have been conducted on human EPCs isolated from PB after long history of diabetes. Thus, lit-
tle is known about the changes occurring in BM in the early stages of diabetes. Therefore, we
intended to investigate the effect of diabetes on BM Lin-/VEGF-R2+ EPCs molecular signature
using isolated cells from Akita diabetic mice and age-matched non-diabetic controls. A micro-
array analysis and gene differential expression (DE) combined with our newly established ana-
lytical methods including TFmiR [10, 11] were used to identify regulatory networks that
potentially drives the diabetic vasculopathy. Unique 3-node Feed Forward Loop (FFL) co-reg-
ulatory motifs consisting of a Transcription factors, miRNA, and co-targeted genes were iden-
tified and validated statistically and biologically.
Research design andmethods
Animals and Lin-/VEGF-R2+ EPCs isolation and characterization
Ethics approval was obtained from University of Sydney Animal Ethics Committee. Ins2A-
kita mice carry a dominant point mutation in the Insulin-2 gene on chromosome-7 resulting
in the development of diabetes at four weeks after birth. As females develop diabetes more
slowly and less stably compared with males, only males heterozygous for Ins2Akita allele
(diabetic) and males homozygous for wildtype Ins2 allele (non-diabetic) were used. Once
diabetes was established (blood glucose level>13.3mmol/L), mice were monitored weekly
for changes in bodyweight and blood glucose levels for 18 weeks. BM Lin-/VEGF-R2+ EPCs
from diabetic and age matched controls were collected as we described before [2, 7]. BM
cells were Fc-blocked, and then stained with APC-mouse-lineage-antibody-cocktail and
FITC-rat-anti-mouse-VEGF-R2. After that, cells were washed and incubated with APC-
magnetic-particles-DM. Hematopoietic lineage markers (CD3e/CD11b/CD45R/Ly-76/Ly-
6G/Ly-6C) were magnetically depleted producing Lin- and Lin+ fractions. The Lin- fraction
was further enrichment magnetically using anti-FITC VEGF-R2 beads producing Lin-/
VEGF-R2+ EPCs. Phenotypic properties of the isolated Lin-/VEGF-R2+ EPCs were charac-
terized using MACSQuant Analyzer-10 flow cytometerand were tested for cobble-stone col-
ony formation, developing tube like structures on Matrigel, Dil-ac-LDL uptake and UEA-I
staining as previously described [2, 7].
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Group design and comparisons
Four experimental groups were established: non-diabetic non-EPCs (Lin+) cells, diabetic non-
EPCs (Lin+) cells, non-diabetic EPCs (Lin-/VEGF-R2+) and diabetic EPCs (Lin-/VEGF-R2+).
The Lin+ cells were used as an internal reference to identify DE occurring not exclusively in
Lin-/VEGF-R2+ cells. Six different comparisons were conducted between the four groups (Fig
1) allowing us to distinguish DE which specifically occurred in Lin-/VEGF-R2+ D-EPCs from
that occurring in other phenotypes of hematopoietic lineage committed BM cells. Hence, only
significant changes in gene expression observed in diabetic vs non-diabetic Lin-/VEGF-R2+
EPCs that did not occur in the Lin+ population were considered in the final analysis.
RNA isolation and array processing
RNA isolation was performed using Qiagen RNeasy-Mini Kit. RNA concentration and integ-
rity were assessed using the BioRad Experion automated electrophoresis system on a RNA
StdSens Chip (BioRad, 700–7159). Later, total-RNA was quality and quantity ascertained
using the Agilent Bioanalyser2100 using NanoChip protocol. A total of 500ng was labelled
using the Ambion Total Prep RNA amplification kit (IL1791). A total of 1.5μg of labelled
cRNA was then prepared for hybridization to theMouse WG-6 V2 beadchip by preparing a
Fig 1. Schematic diagram showing the study experimental design, the integrative computational analysis, and the validation procedures used in this
study. See Fig 2 for the list of comparisons conducted between the pairs of samples.
https://doi.org/10.1371/journal.pone.0200194.g001
Diabetes impaired BM-EPCs gene regulatory network
PLOSONE | https://doi.org/10.1371/journal.pone.0200194 July 11, 2018 3 / 20
probe cocktail (cRNA at 0.05μg/μl) that includes GEX-HYB Hybridization Buffer. A total
hybridization volume of 30μl was prepared for each sample and loaded into a single array on
the beadchip, which was hybridized as outlined in the Illumina manual protocols. Chips were
then coupled with Cy3 and scanned in the Illumina iScan scanner and its software, GenomeS-
tudio, converted the signal on the array into a TXT file for analysis.
Data processing
The research aim is to unveil the molecular mechanisms and mutual interactions between
deregulated coding and non-coding RNAs that underlie the early stages of diabetes in BM
Lin-/VEGF-R2+ EPCs. Therefore, it was sufficient to measure the expression at single time
point, but only after ensuring developing the corresponding phenotype. Raw expression values
were background corrected, log2 transformed and quantile normalized using the lumiR pack-
age [12] of the Bioconductor suite [13]. Expression profiles of redundant probe sets were
merged by computing the mean of all probes related to single genes as reported previously
[11]. A list of 266 diabetic-associated genes was downloaded from the Mouse Genome Infor-
matics (MGI) database [14].
Differential expression analysis
The six comparisons were compared by DE analysis using three methods each: significance
analysis of microarray (SAM) [15], moderated t-test [16], and area-under-the-curve of the
receiver operator characteristics (AUC ROC) [16]. Genes that were classified as DE by at least
two of those three methods were included in the list of DE-genes. We focused on genes that
are exclusively involved in the fourth comparison only. Expression heat-maps and PCA-plots
were generated by R [17].
miRNA enrichment
We predicted the miRNAs associated with the list of DE-genes by determining the set of miR-
NAs whose target genes and regulator TFs are significantly enriched within the DE gene-set
using the hypergeometric distribution function followed by the Benjamini-Hochberg adjust-
ment with a cutoff value of 0.01. The miRNA target-genes and the miRNA regulators were
compiled from the regulatory databases listed in [10].
Construction of TF-miRNA regulatory networks and motif modules
The regulatory interactions between the DE-genes and their targets/regulators as well as the
interactions between the enriched miRNAs and their regulators/targets were retrieved from
the databases of TFmiR webserver [10]. Only regulatory interactions that are supported by
experimental evidence were included in this analysis. To identify central-hubs (key network-
players), we computed the degree centrality measure for the entire network using R igraph-
package [18] and highlighted the top 10% highest centrality nodes of the TFs/genes and miR-
NAs. Next, 3-node FFL-motifs (recurring network patterns consisting of a miRNA, a TF, and
a joint target gene) were characterized using the computational procedure described in [10].
The networks and co-regulatory motifs were visualized with Cytoscape-V3.3.0 [19].
Network validation and assessment of key player-nodes
1- Statistical validation: Significance of the detected motifs. To evaluate the significance
of each co-regulatory motif, we compared how often it occurs in the full regulatory network
against the number of times it is detected in ensembles of randomized networks preserving the
Diabetes impaired BM-EPCs gene regulatory network
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same node degrees. The randomization procedure is explained in detail in [10]. The random
networks were constructed 100-times and compared to the real network. The p-value was cal-
culated as
p value ¼ Nh
Nr
where Nh is the number of random times that a certain motif type is detected more than or
equal to its number in the real network, and Nr is 100. Only motifs having p-value<0.05 were
considered for further analysis.
2- Semantic validation: Functional homogeneity within the motif nodes. In order to
assess the biological relevance of the identified network motifs and to better understand their
functional roles, we analyzed the Gene Ontology (GO) semantic similarity for all pairs of genes
regulated by the TF or the miRNA of each motif. The GoSemSim R-package [20] was used to
calculate the semantic similarity scores according to the GO annotations. Statistical signifi-
cance was determined by randomly selecting the same number of co-regulated genes (genes
targeted by either the TFs or the miRNA) from all Entrez genes with GO annotations, and
computing their similarity scores. The permutation procedure was repeated 100-times. Then,
Kolmogorov-Smirnov test was utilized to check whether the functional similarity scores of all
gene-pairs composing a regulatory motif are significantly higher than that of randomly
selected pairs.
3- Over-representation analysis for genes and miRNAs. The functional enrichment
analysis was conducted as we reported previously [21]. Briefly, enriched KEGG Pathways and
GO functional categories were identified using the DAVID tool [22]. For this, we analyzed
which pathway/functional terms were annotated to at least 2 genes and were statistically over-
represented in the study gene-set against the full mouse genome (control). Enrichment was
evaluated through the hyper-geometric test (p-value0.05). Enrichment analysis of the miR-
NAs sets was performed using the TAM tool [23].
Results
We developed and applied an integrative approach to conduct combinatorial regulatory net-
work analysis in the context of early diabetes in Lin-/VEGF-R2+ EPCs with the aim of identify-
ing the major genetic drivers and the essential network modules that could possibly dissect
how diabetes impairs EPC functions. Fig 1 illustrates the implemented integrative approach
including the study experimental design, the downstream analysis, and the applied validation
steps.
Establishing diabetes in mice
By 22 weeks of age (time of BM collection) the mean bodyweights for non-diabetic and dia-
betic mice were 37.2±3.1g and 23.0±2.2g, respectively (p<0.0001). The mean blood glucose
levels of non-diabetic and diabetic mice were 9.3±1.4[7.5–10.0]mmol/L and 33.1±2.9[27.5–
33.4]mmol/L, respectively (p<0.0001). The mean HbA1c was higher in the Akita group (11.5
±0.5%) compared to the control (4.6±0.3%).
Cell numbers, characteristics, function and RNA quality and quantity
The mean percentages of Lin+ and Lin−/VEGF-R2+ cells in BM nucleated cells fraction were
80.7±4.7% and 4.5±2.1%, respectively. After adjusting for bodyweight, the number of Lin−/
VEGF-R2+ EPCs in diabetic BM 5.6[4.0–9.3]×104 /g bodyweight was slightly higher than non-
diabetic 5.0[2.9–7.2]×104 /g bodyweight.
Diabetes impaired BM-EPCs gene regulatory network
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Akita non-diabetic and diabetic Lin-/VEGF-R2+ cells demonstrated the inherent and essen-
tial properties of EPCs such as cobble-stone colony formation, ability to be cultured and pas-
saged, phenotypic analysis on flow cytometry, developing tube like structures on Matrigel, Dil-
acLDL uptake and staining for UEA-I.
Akita mice develop diabetes spontaneously, as a result of a progressive loss of beta-cell func-
tion and decreased pancreatic beta-cell density, mimics DM type 1 but do not show late stage
complications. This model demonstrated that early diabetic changes can be detected in Lin-/
VEGF-R2+ EPCs function such as lose of mobilize potential from BM to PB and the reduction
in their capability to migrate towards injured blood vessels and repair mechanism.
Only samples that had a high RNA yield and RQI7 (mean was 8.9) were selected for
microarray analysis. For the non-diabetic and diabetic Lin+ fraction, the concentrations of
extracted RNAs were 202.7±122.0ng/μl and 283.0±114.7ng/μl, respectively (p = 0.108). The
Lin-/VEGF-R2+ EPCs fraction yielded 97.2±80.0ng/μl RNA from non-diabetics and 157.3
±87.6ng/μl RNA from diabetics (p = 0.198). Before microarray processing, the RNA integrity
was measured again and the RNA integrity number was7 (mean 8.6) in all samples.
Differential expression analysis
Comparing non-diabetic Lin-/VEGF-R2+ EPCs with Lin-/VEGF-R2+ D-EPCs identified 80
DE-genes that were exclusively detected in the fourth comparison as shown in the Venn dia-
grams (Fig 2). The 80 DE-genes were significantly associated with the known ‘diabetes-associ-
ated genes’ list (hyper-geometric test, p = 0.0319), see methods section. Out of the 80 DE-
genes (S1 Table), three genes Clcnka (downregulated) and Ptf1a and Pik3c2a (both up-regu-
lated) are shared with the diabetes-associated genes list. A heat-map was generated to show the
relative gene expression among the four groups (Fig 3A). Then non-diabetic and Lin-/
VEGF-R2+ D-EPCs were selected to generate a heat-map for the relative expression of the 80
DE-genes (Fig 3B). To show how the 80 DE-genes are separated between non-diabetic and
Lin-/VEGF-R2+ D-EPCs, PCA analysis was conducted (S1 Fig). The PCA clustered the DE-
genes into down-regulated and up-regulated genes based on their relative expression levels.
miRNA enrichment analysis
27 miRNAs were identified by determining the set of miRNAs whose target genes and regula-
tor TFs were significantly enriched within the 80 DE-genes. The identified miRNAs are:mir-1,
mir-133a,mir-200,mir-429,mir-141,mir-451,mir-709,mir-103-1,mir-148b,mir-182,mir-96,
mir-183,mir-205,mir-378,mir-146a,mir-124,mir-210-3p, let-7c,mir-139-5p,mir-124a,mir-
223,mir-145,mir-196,mir-200a,mir-200b,mir-29c,mir-27b. The biological role of these miR-
NAs was assessed by linking them to functional and disease annotations via Over Representa-
tion Analysis, S2 Table. Interestingly, the identified miRNAs were significantly enriched with
EPC-related biological processes such as diabetes mellitus (p< 0.013), cell proliferation (p-
value 0.0008), cell differentiation (p-value 0.007), cell fate determination (p<0.03), hematopoi-
esis (p<0.035), glucose metabolism (p-value<0.029), and carbohydrate metabolism (p-value
0.0001).
Construction of TF-miRNAmediated regulatory network
Next, we constructed a gene regulatory network (GRN) that represents the combinatorial reg-
ulatory interactions between the DE-genes in Lin-/VEGF-R2+ D-EPCs and the enriched miR-
NAs. The GRN contains three types of nodes, namely miRNAs, TFs (nodes regulating genes
and miRNAs), and target genes (nodes regulated by TFs or miRNAs), S2 Fig. We refer to this
GRN-network as “D-EPC-GRN”. To evaluate the contribution of each node-type in the
Diabetes impaired BM-EPCs gene regulatory network
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D-EPC-GRN stability and robustness, the number of connections that each node is involved
in (also termed node-degree centrality) were computed and ranked according to this number.
The most connected nodes (miRNAs, TFs, and target genes) were candidates for central-hubs
that could possibly drive the diabetes etiology in Lin-/VEGF-R2+ EPCs and thus could act as
potential master-regulators. Eleven TF/gene hubs were identified (Myc, Pparg, Gata1,Max,
Cebpa, Ahr, Tbp, Trp53, Foxo1, Foxo4, and Yy1) and two miRNA hubs (mir-709, and mir-139-
5p) (S2 Fig). Among them, Foxo1,Myc, Yy1, and Cebpa were reported in literature to be essen-
tial TFs in regulating diabetes [24–27].
Identification of TF-miRNA co-regulatory motifs
Biological networks often contain recurring interconnection patterns known as FFL motifs
[28] that control different aspects of cell functions and diseases [29, 30]. Therefore, the pres-
ence of 3-node co-regulatory FFL-motifs comprising the DE TFs/genes and the miRNAs in
the D-EPC-GRN was checked. This led to the detection of 55 significant co-regulatory motifs
in the constructed D-EPC-GRN (S3 Table). The statistical significance of the motifs was tested
by comparing their count in the real network to their counts in randomized variants of these
networks preserving the same node degrees.
Fig 2. Venn diagrams showing overlapping differentially expressed genes among the six comparisons. (A) Comparisons 1–5, (B) comparisons 1–4 and 6. In both
Venn diagrams the same 80 genes were found specific to comparison 4 (non-diabetic EPCs vs D-EPCs).
https://doi.org/10.1371/journal.pone.0200194.g002
Diabetes impaired BM-EPCs gene regulatory network
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Fig 3. Heat maps of the microarray analysis results. (A):Differentially expressed genes in all 36 samples. Green-spots
represent down-regulated genes, and red-spots represent up-regulated genes. The blue color represents D-EPCs, the orange
color represents the non-diabetic EPCs, the blue pink represents diabetic Lin+, and the gray color represents the non-diabetic
Lin+. (B): 80 core enrichment genes in comparison-4 (non-diabetic vs D-EPCs). Green spots represent down-regulated genes,
and red spots represent up-regulated genes. The order of genes is obtained by hierarchical clustering. The orange color
represents the non-diabetic EPCs while the blue color represents the D-EPCs.
https://doi.org/10.1371/journal.pone.0200194.g003
Diabetes impaired BM-EPCs gene regulatory network
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Fig 4 illustrates six interesting motifs detected in the D-EPC-GRN that appear to have
strong relevance to the regulation of murine diabetes. Each of the motifs contains a specific
EPC central gene and/or central miRNA that are regulating a deregulated set of target genes
including two of the three identified diabetes-associated genes (Clcnck and Ptf1a) in motifs 14
and 19.
Next, we assessed the biological evidence of these motifs to better understand their func-
tional roles in driving the diabetes in Lin-/VEGF-R2+ EPCs. To this end, we calculated the
functional similarity scores between co-regulated gene-pairs as a measure of their functional
homogeneity and integrity. The distribution of the resulting similarity scores was compared to
the similarity score distribution of randomly selected gene-pairs (p<8.8e-5, Kolmogorov-Smir-
nov test), Fig 5. The results show that the co-regulated genes have significantly more similar
cellular functions than the randomly selected genes. This indicates that these six FFL-motifs
could potentially hint at dissecting the related dysfunctions and molecular changes in Lin-/
VEGF-R2+ EPCs during early diabetes.
Discussion
The direct effect of high glucose on EPCs function is still controversial with most studies being
done on human EPCs. As is the case for research into surface markers of EPCs, in which con-
flicting results have sometimes been presented, the field of diabetes induced changes in EPCs
is replete with paradoxical or even contradictory results. One factor contributing to the confu-
sion is the fact that the condition “diabetes” when used in experiments or studies is ill-defined.
It comprises patients with quite different stages of the disease and different complications.
Another critical point naturally is the definition of EPCs, which also varies from study to
study. Despite a certain degree of confusion, the mechanisms of diabetes related changes
become clearer as more and more studies examining EPCs in diabetes from different angles
become available. One of the most significant findings in Akita model come from the analysis
of gene-expression data of genes known to be involved in Lin-/VEGF-R2+ function and mobi-
lization. This showed that early diabetes leads to significant changes in Lin-/VEGF-R2+ EPCs
function.
The effect of diabetes on Lin-/VEGF-R2+ EPCs number and function has previously been
investigated. Although EPC-types and the methods used were quite different they all returned
significant dysfunction of Lin-/VEGF-R2+ D-EPCs. We previously demonstrated that Lin-/
VEGF-R2+ EPCs defined as Lin−/VEGF-R2+ were more primitive than other Lin-/VEGF-R2+
EPCs described in literature and due to diabetes they had limited vascular repair capacity
attributed to their impaired ability to mobilize, rather than their ability to proliferate, leading
to Lin-/VEGF-R2+ EPCs BM trapping [2, 7, 31]. Since the exact mechanism underlying this
impaired mobilization is still unknown, identifying the responsible genes, TFs, miRNAs, may
lead to valuable information. Numerous explanations for Lin-/VEGF-R2+ D-EPCs dysfunction
have been proposed, including increased oxidative stress, NADPH oxidase activation, altered
nitric oxide pathway and increased inflammatory cytokines [32]. However, and since diabetes
is a complex pathophysiological syndrome, it is unlikely that Lin-/VEGF-R2+ D-EPCs dysfunc-
tion could be explained by a single independent mechanism. Hence, this study used microar-
ray, well-established integrative data analysis, and multiple validation procedures [21] to
identify genes, TFs and miRNAs in Lin-/VEGF-R2+ D-EPCs and could potentially lead to their
dysfunction. Consequently, we identified a novel TF-miRNA GRN specific to Lin-/VEGF-R2+
D-EPCs (D-EPC-GRN), putative genomic drivers (TFs and miRNAs) and significant FFL net-
work modules that involve dysregulated TFs/genes, associated miRNAs as well as diabetes-
associated genes. In the Lin-/VEGF-R2+ D-EPC-GRN, 13 central-hubs were identified (11
Diabetes impaired BM-EPCs gene regulatory network
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Fig 4. Six interesting co-regulatory motifs suggesting a cooperative functional role between the identified central-hubs and
their potential partners of miRNAs, TFs, and target genes in the D-EPC-GRN network. TFs are represented by a turquoise
triangle whereas miRNAs are shown as orange squares. Pink nodes denote the common target genes and the grey nodes depict
the co-regulated genes.
https://doi.org/10.1371/journal.pone.0200194.g004
Diabetes impaired BM-EPCs gene regulatory network
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genes: Pparg, Foxo1, Foxo4, Ahr, Trp53, Gata1, Yy1, Max,Myc, Cebpa, Tbp, and 2 miRNAs:
mir-139-5p,mir-709) as potential master-regulatory genes/miRNAs or essential genetic-drivers
of the molecular pathology of Lin-/VEGF-R2+ D-EPCs.
Ppara and Pparg genes that are associated with type-2 diabetes, hepatic metabolic response
to diabetes, insulin resistance through their expression in vasculature cells and EPC trafficking
regulation [33], were significantly upregulated. Activation and over-expression of Ppara sup-
presses EPCs mobilization and hypoxia induced homing, which occur through the inhibition
of theHIF-1?/SDF-1 pathway [34]. In this study, Ppara upregulation in Lin-/VEGF-R2+
D-EPC-GRN was regulated mainly by Pparg and Ahr central-hubs and was consistent with an
anti-angiogenic role and impairedHIF-1?/SDF-1-Ppara axis.
Foxo1 and Foxo4 upregulation was implicated in diabetes, diabetic complications and car-
diovascular disease, through impairing proliferation and differentiation, and abnormal cyto-
kine expression, inflammation, and resistance to oxidative stress [35]. Two of the major
central-hubs in Lin-/VEGF-R2+ D-EPC-GRN were Foxo1 and Foxo4 andmir-139-5p was iden-
tified as their key regulator, which also regulates other key diabetic TFs (Zeb1,Usf1, and Xlr4b)
(Fig 6).
Fig 5. Functional homogeneity of the visualized six motifs. Cumulative distribution of GO functional semantic scores of gene pairs of co-regulated genes in the
examined six motifs (red) versus randomly selected genes (black). The p-value was calculated using the Kolmogorov-Smirnov test.
https://doi.org/10.1371/journal.pone.0200194.g005
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We also found that Gata1 regulatesmir-139-5p and Zeb1, while Pou3f1 regulatesmir-139-5p
and Foxo1. At the same time,mir-139-5p suppresses Zeb1, Foxo1, Usf1 and Xlr4b (Supplemen-
tary material motifs 4 and 11). This led to the identification of an important diabetic regulatory
mechanism in impaired Lin-/VEGF-R2+ EPCs. The activity of Foxo family is tightly regulated
by post-translational modification, including phosphorylation, acetylation, and ubiquitylation.
Foxo1 plays a crucial role in regulating gluconeogenesis and glycogenolysis by insulin signaling
[36]. Another diabetic DE-gene in the D-EPC-GRN is Pik3c2a, which encodes for the Pik3c2a
enzyme that is activated by insulin. Thus, in diabetes Pik3c2a enzyme activity is expected to be
suppressed, which may result in up-regulation of Foxo1. In our study, both Pik3c2a and Ptf1a
(annotated as diabetic-specific genes in the MGI database) were differentially up-regulated in
the D-EPC-GRN. Pik3c2a as well as Foxo4 were regulated by Ikzf1 (linked to type-1 diabetes
[37]) whereas Ptf1awas regulated by the Ahr. This suggests essential regulatory roles of Lin-/
VEGF-R2+ EPCs’ Foxo4 and Ahr in the early onset of diabetes.
The other mechanism by which Foxo may regulate Lin-/VEGF-R2+ D-EPCs is via the oxi-
dative stress activated P66shc-Akt-Foxo pathway [38]. P66shc was reported to be involved in
EPC dysfunction due to hyperglycemia [39]. In this study, Foxo1&4 were DE in Lin-/
VEGF-R2+ D-EPCs, which may contribute to Lin-/VEGF-R2+ D-EPCs dysfunction observed
through a negative effect of hyperglycemia-induced oxidative stress on the regulatory interac-
tion between Pik3c2a/Foxo1 and the possible activation of the P66shc-Akt-Foxo pathway. The
fact that Pik3c2a is up-regulated in Lin-/VEGF-R2+ D-EPCs is supported by studies that dem-
onstrated an inhibitory effect of up-regulated Pik3c2a on epithelial and cancer cell prolifera-
tion, migration and colony formation [40] illustrating the observed dysfunction of Lin-/
VEGF-R2+ D-EPCs. Additionally, a recent study showed decreased expression of EPC Pik3c2a
in coronary artery disease reducing their angiogenic and vasculogenic abilities [41], which
highlights its importance in blood vessels repair that is impaired in diabetes.
Ptf1a is a pancreatic TF known for its role in pancreatic development and differentiation
[42]. Lin-/VEGF-R2+ D-EPCs showed upregulation of Ptf1a that may be a compensatory
action in diabetes. In parallel, the Foxo4-Ptf1a pathway plays a central role in directing the dif-
ferentiation of retinal progenitor cells [43]. Thus, impaired Foxo4-Ptf1a pathway may cause
diabetic retinopathy.
The implication of Ahr in diabetes or in EPC function has never been described before. Ahr
is a cytosolic TF that when activated translocate to the nucleus altering the transcription of tar-
get genes. Here, Ahr was DE and its role in the D-EPC-GRN seems to be fundamental. It is
one of the central-hubs, regulating Clcnka and Ptf1a, two of the three diabetic genes. More-
over, Ahr is also prominent in the 3-node co-regulatory FFL-motifs (Fig 4) comprising the DE
TFs/genes and the miRNAs in the D-EPC-GRN where Ahr activates Foxa2 and Nfkb1.Mir-
124was also found to repress Foxa2 and Ahr as well as Sox9, all of which important key genes
in diabetes. Therefore, we believe that Ahr plays a significant role in controlling D-EPC.
Clcnka is a poorly studied gene that we found to be downregulated in Lin-/VEGF-R2+
D-EPCs. Mutations in this gene have been linked to dysfunctional endothelium, hypertension
and cardio-renal axis dysfunction [44]. Therefore, we assume that diabetes influenced Clcnka
downregulation contributes to the capacity of Lin-/VEGF-R2+ EPCs to regenerate endothe-
lium in organs such as kidneys, which are damaged in diabetes. Chloride regulation is not
really well understood but it has been related to the regulation of proinsulin conversion to
active-insulin. Clcn3(-/-) mice demonstrate impaired insulin secretion demonstrating an
important role of chloride channel proteins in insulin processing and secretion [45], which
supports the implication of Clcnka in impaired function of D- Lin-/VEGF-R2+ EPCs especially
via Ahr andmir-124 as seen in Fig 4. It is also important to mention that hereditary diabetes
insipidus patients demonstrated mutated Clcnka [46].
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This study also identified 27 miRNAs that are associated with the regulation of the 80 DE
diabetic-genes, which were statistically enriched with EPC-related biological processes such as
cell proliferation, differentiation, cell-fate determination, hematopoiesis, glucose metabolism,
and diabetes mellitus. Many of the 27 miRNAs were previously found to be associated with
Fig 6. Visualization of all motifs that include mir-139-5p and its interactions with central-hubs.
https://doi.org/10.1371/journal.pone.0200194.g006
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progenitor cells function and diabetes complications. For instance,mir-451 level has been
reported to be lower in hematopoietic progenitor cells as compared to controls [47]. In this study
mir-451 is DE in non-hematopoietic progenitor cells and is regulated byMyc, a chief regulatory
gene in D-EPC-GRN.Myc activation is reported to regulate cell growth (upregulates rRNA), cell
proliferation (upregulates cyclins, downregulates p21), differentiation, stem cell self-renewal, and
apoptosis (downregulates Bcl-2) [47]. Forced expression of four mouse stem cell factors (Oct4,
Sox2,Klf4, andMyc) changes the phenotype of rat endothelial cells to vascular progenitor cells
[48]. Such vascular progenitor cells share cardinal properties with our Lin-/VEGF-R2+ EPCs sam-
ples whereMyc was DE. This emphasizes the isolation efficiency of our Lin-/VEGF-R2+ EPCs.
Additionally,mir-223 is regulated by Cebpa through Foxq1. Sincemir-223 expression is usually
high in essential thrombocythemia and primary myelofibrosis group [49], this may indicate the
importance of this miRNA in stem cell differentiation into the myeloid lineage.
Importantly, we found an interesting relationship between Cebpa which regulateMyc andmir-
709 at the same time, which then repressesMyc activation through a negative feedback mecha-
nism. In parallel to this,mir-709 suppresses the expression of three other genes, Slc2a13, Lhx3 and
Esrra, which are all activated byMyc underlining the central role of bothMyc andmir-709 in
D-EPC function (Panels A and B in S3 Fig). Potential therapies can be directed against such genes
and miRNAs to alter the fate of the Lin-/VEGF-R2+ D-EPCs and restore their function.
Interestingly, our study identified multiple miRNAs (miR-1, miR-206,mir-133a,mir-103,
mir-107, andmir-223) that have been linked to diabetes. For example, in both in vivo and in
vitro experiments, increased levels of glucose in myocardiomyctes led to significant upregula-
tion ofmiR-1 andmiR-206 with resulting modulation ofHsp60 leading to accelerated glucose-
mediated apoptosis in cardiomyocetes [50] andmir-133a was downregulated in diabetic car-
diomyopathy [51]. Altered activation of PI3K and SREBP-1cmay explain the defective regula-
tion ofmiR-1 andmiR-133a expression in response to insulin in muscle of type-2 diabetic
patients [52].Mir-103 andmir-107 were noted to be upregulated in obese mice and were sub-
sequently found to have a key role in insulin sensitivity making them potential targets for the
treatment of type-2 diabetes [53]. Alsomir-223 was reported to be associated with type-2 dia-
betes [54].
Similarly, other miRNAs that were identified in this study (mir-223,mir-205, andmir-210)
are linked with proliferation and differentiation of hematopoietic progenitor cells. Analyses of
expression profiles indicated thatmir-223 expression decreases as cells mature during mono-
cytic, erythroid, and mast cell differentiation.mir-223 down-regulation during erythropoiesis
is required for erythrocyte proliferation and differentiation at progenitor and precursor level
[55]. In Lin-/VEGF-R2+ D-EPCsmir-223 is suppressingMef2c, which is activated by Nkx2-2
(Fig 4). This is a novel relationship that has not been reported before.Mir-205 plays a role in
directing stem cell fate [56]. A study on mammary-gland progenitor cells showed thatmiR-205
overexpression led to an expansion of the progenitor-cell population, decreased cell size and
increased cellular proliferation [56]. In this study,mir-210-3p is able to suppress Nfkb1 that is
activated by Ahr and/or Gata1 (Fig 4).Mir-210 in particular, has been studied for its effects in
rescuing cardiac function after myocardial infarcts via the upregulation of angiogenesis and
inhibition of cardiomyocyte apoptosis [57].
There is strong evidence that supports the concept of diabetes altering the number of circu-
lating Lin-/VEGF-R2+ EPCs (60), which are likely trapped in BM, and impairing their vasore-
parative potential resulting in premature senescence (61). Thus, it is likely that diabetes
influences the expression of genes in Lin-/VEGF-R2+ EPCs that are specific to those pathways.
Although many studies reported that diabetes causes reduction in PB EPC number [5], others
have reported an increase in EPC number in the circulation [58] while we did not find any sig-
nificant effect of diabetes in mice [7]. We previously reported downregulation of Sdf-1 and Sele
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genes in Lin-/VEGF-R2+ D-EPCs [31]. Since Lin-/VEGF-R2+ EPCs have the ability to produce
SDF-1 [59] and SDF-1/Cxcr4 is a known EPC mobilization and maturation axis [60], this
downregulation of SDF-1may contribute to the impaired mobilization of Lin-/VEGF-R2+
D-EPCs. Thus the observed decrease of Lin-/VEGF-R2+ D-EPCs in PB could be attributed to
the impaired mobilization ability from BM to PB leading to EPC BM-trapping and not to the
impaired proliferation. Based on the MGI database [14] eNOS, Sdf-1, Cxcr4, and Sele are all
specific EPC genes but in this study they were not among the DE gene list. Despite that, we
found that these genes are regulated by some of the central-hub genes and miRNAs in our
D-EPC-GRN in particularmir-139-5p,mir-709, Gata1, Ppara, and Tbp (S4 Table). It should be
mentioned that these regulatory interactions are based on predicted evidences through
regNET database [61] rather than experimental evidence.
Dysfunction of Nos3 signaling has also been implicated in EPC dysfunction in diabetes. The
dysfunction has been linked with decreased Nos3 activity [62] and the Nos3 deficient (NOS3-/-)
mouse had impaired EPC mobilization and angiogenesis [62]. The expression and phosphory-
lation of Nos3 are essential for the survival, migration and angiogenesis facilitated by Lin-/
VEGF-R2+ EPCs and ECs [63]. Human EPCs that overexpress Nos3 have increased migratory
potential, increased ability to incorporate into tube-like structures and to differentiate into
endothelial spindle-like structures [64]. We did not observe a significant change in Nos3
expression in Lin-/VEGF-R2+ D-EPCs. Based on the predicted analysis Nos3 is regulated by
mir-139-5p, Gata1 and Ppara. We previously reported that Nos3 expression in BM Lin-/
VEGF-R2+ EPCs was very low indicating that they are early progenitor cells [31] since late
EPCs have higher expression Nos3 levels [65].
In conclusion we were able to detect associated genes, miRNAs, and collaborative network
modules that are affected by early stages of diabetes in BM Lin-/VEGF-R2+ EPCs. To our
knowledge, this is the first report that predicts and unravels the combinatorial regulatory inter-
actions and genetic alterations that are specific to Lin-/VEGF-R2+ D-EPCs. Specific findings
such as Ppar signaling pathway and Foxo1&4-mic139-5p-Gata1-Pou3f1 axis and their role in
Lin-/VEGF-R2+ EPC proliferation and differentiation and in insulin signaling pathway,
Pik3c2a-Ptf1a-Foxo4-Ahr axis and its role in early onset of diabetes and blood vessel repair,
P66shc-Akt-Foxo pathway and its role in oxidative stress associated diabetes and EPC dysfunc-
tion, as well as Cebpa-Myc-mic-709 axis and its role in D-EPC function may lead to novel ther-
apeutic strategies for mobilization of Lin-/VEGF-R2+ EPCs and the treatment of diabetic
vascular complications such as diabetic retinopathy, nephropathy and cardiovascular disease.
Supporting information
S1 Table. List of all differentially expressed genes. There were 80 genes specific to compari-
son 4 (non-diabetic EPC vs D-EPC) and they were all annotated in theMouse WG-6 V2 bead-
chip. There were only 3 genes that are diabetes related. They are underlined and italic
formatted. Genes with positive LFC Diff values are up regulated in D-EPC.
(DOC)
S2 Table. The annotated functional terms and diseases in the identified miRNA list.
(DOC)
S3 Table. The complete list of detected TF-miRNA co-regulatory motifs.
(DOC)
S4 Table. Predicted interactions between EPC specific functional DE-genes (Cxcr4, Nos3,
Cxcl12) and genes in our D-EPC-GRN.
(DOC)
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S1 Fig. Principal Component Analysis (PCA) for all identified 80 genes in comparison 4
(non-diabetic and diabetic EPCs). Genes are clustered based on relative gene expression and
are given a color-coded sphere. Green spheres are genes that are downregulated. Red spheres
are genes that are up-regulated.
(TIF)
S2 Fig. The entire TF-miRNA network (D-EPC-GRN) constructed from the differentially
expressed genes, their targets and regulators as well as the enriched miRNAs and their tar-
gets and regulators. Nodes in turquoise triangle denote TFs. The miRNAs are represented in
orange square shapes. Grey circles represent the target genes. Larger nodes (forming the inner
circle) are the identified central-hubs that might act as putative driver TFs/miRNAs. Black
solid arrows indicate the regulation of TFs to target genes. Black dotted arrows indicate the
regulations of TFs to miRNAs. The repression of miRNAs to their target genes is represented
in red dotted arrows.
(TIF)
S3 Fig. Panels A and B. Visualization of all motifs that contain mir-709 and its interactions
with central-hubs and other genes.
(EPS)
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